The India Heart Valves Market is undergoing a transformative shift with the rapid adoption of Transcatheter Aortic Valve Replacement (TAVR), a minimally invasive procedure that is redefining the standard of care for patients with severe aortic stenosis. This procedure allows for heart valve replacement without the need for open-heart surgery, significantly reducing recovery times and expanding treatment options for high-risk patients.
TAVR is a minimally invasive approach for treating patients with severe aortic stenosis who are at high or prohibitive risk for traditional open-heart surgery. Worldwide, more than 120,000 patients undergo TAVR annually across 50 countries. In India, over 5,000 TAVR procedures have been performed over the last 10 years, with numbers accelerating rapidly. Manipal Hospitals Kolkata recently completed 50 successful TAVR cases, establishing itself as a regional market leader in Eastern India.
Recent product launches are accelerating this growth. Medtronic launched its Evolut FX+ TAVR system in India after receiving CDSCO approval in June 2025. The system is designed with improved coronary access, featuring significantly larger coronary access windows than previous Evolut valves. This innovation is critical for the lifetime management of patients, particularly as TAVR is increasingly used in younger patients who may require future coronary interventions.
In a significant development, VitaFlow Liberty® successfully completed its first 22 commercial implantations in India in 2025. This system is the world's first electrically retrievable TAVI system, offering physicians the ability to recapture and reposition the valve during implantation for optimal placement. The procedures were performed by expert teams at leading Indian medical centers, including CH.
Local innovation is also thriving. Zydus MedTech has partnered with Braile Biomedica to expand TAVI technology across Europe and India. The expansion of TAVI indications to all-risk patients has accelerated its adoption in recent years. Sahajanand Medical Technologies has also received ₹45.13 crore from the Technology Development Board for the product enhancement and commercialization of TAVI technology.
TAVR offers significant advantages over traditional open-heart surgery. In contrast to conventional surgeries, TAVR bypasses the opening of the chest and minimizes risks of anesthesia. Patients usually go home in a day or two, and such a recovery is nothing less than a revolution. The procedure success rate is 95-98%, with a 30-day survival rate of 97-99% and significant symptom improvement in 90-95% of patients. As awareness grows and more centers adopt this technology, TAVR is poised to become the standard of care for an increasing number of patients with valvular heart disease in India.